New Pancreatic Cancer Drug Daraxonrasib Receives Enthusiastic Reception at ASCO 2026
New Cancer Pill Given Standing Ovation at Oncology Conference
Newsweek
Image: Newsweek
At the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, the new pancreatic cancer drug daraxonrasib received a standing ovation after showing nearly double survival rates in late-stage trials. The drug targets a previously 'undruggable' KRAS mutation, offering hope for patients with metastatic pancreatic cancer.
- 01Daraxonrasib reduced the risk of death by 60% in patients with previously treated metastatic pancreatic cancer.
- 02The drug is the first of a new class of 'RAS(ON) multi-selective inhibitors' targeting multiple KRAS variants.
- 03In the Phase 3 RASolute 302 trial, patients on daraxonrasib had an overall survival of 13.2 months compared to 6.6 months for chemotherapy.
- 04The FDA has granted daraxonrasib Breakthrough Therapy Designation and Orphan Drug Designation, expediting its review.
- 05Daraxonrasib is now being tested in earlier treatment lines and in combination with chemotherapy for various cancers.
Advertisement
In-Article Ad
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, oncologists celebrated the unveiling of daraxonrasib, a new drug for pancreatic cancer, with a standing ovation lasting nearly a minute. Lead investigator Dr. Brian M. Wolpin from Dana-Farber Cancer Institute presented trial results showing that the drug nearly doubled survival rates in late-stage pancreatic cancer patients, cutting the risk of death by 60%. This drug targets mutations in the KRAS gene, a significant breakthrough as these mutations have long been considered 'undruggable'. The Phase 3 RASolute 302 trial demonstrated that patients treated with daraxonrasib had an overall survival of 13.2 months compared to 6.6 months for those receiving standard chemotherapy. The FDA is expediting the review process for this promising treatment, which is also being tested for other cancers driven by RAS mutations. Experts have hailed the findings as potentially transformative for pancreatic cancer treatment.
Advertisement
In-Article Ad
The introduction of daraxonrasib could significantly improve survival rates for pancreatic cancer patients, addressing a critical need for effective treatments.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of daraxonrasib for pancreatic cancer treatment?
Connecting to poll...
More about Dana-Farber Cancer Institute
Read the original article
Visit the source for the complete story.